Files and links (1)
Published VersionCC BY-NC-ND V4.0, Open Access
Journal article
Impairing memory reconsolidation with propranolol in healthy and clinical samples: a meta-analysis
Journal of Psychiatry and Neuroscience, Vol.47(2), pp.E109-E122
2022
PMID: 35361699
Abstract
Background:
Reconsolidation impairment using propranolol is a novel intervention for mental disorders with an emotional memory at their core. In this systematic review and meta-analysis, we examined the evidence for this intervention in healthy and clinical adult samples.
Methods:
We searched 8 databases for randomized, double-blind studies that involved at least 1 propranolol group and 1 placebo group. We conducted a meta-analysis of 14 studies (n = 478) in healthy adults and 12 studies in clinical samples (n = 446).
Results:
Compared to placebo, reconsolidation impairment under propranolol resulted in reduced recall of aversive material and cue-elicited conditioned emotional responses in healthy adults, as evidenced by an effect size (Hedges g) of −0.51 (p = 0.002, 2-tailed). Moreover, compared to placebo, reconsolidation impairment under propranolol alleviated psychiatric symptoms and reduced cue-elicited reactivity in clinical samples with posttraumatic stress disorder, addiction or phobia (g = −0.42, p = 0.010). Limitations: Methodological differences between studies posed an obstacle for identifying sources of heterogeneity.
Conclusion:
Reconsolidation impairment is a robust, well replicated phenomenon in humans. Its clinical use is promising and deserves further controlled investigation.
Details
- Title
- Impairing memory reconsolidation with propranolol in healthy and clinical samples: a meta-analysis
- Authors
- Sereena Pigeon - Douglas Mental Health University InstituteMichelle Lonergan - Douglas Mental Health University InstituteOlivia Rotondo - McGill UniversityRoger K Pitman - Harvard UniversityAlain Brunet (Corresponding Author) - McGill University
- Publication details
- Journal of Psychiatry and Neuroscience, Vol.47(2), pp.E109-E122
- Publisher
- Canadian Medical Association, Association Medicale Canadienne
- Date published
- 2022
- DOI
- 10.1503/jpn.210057
- ISSN
- 1488-2434; 1180-4882
- PMID
- 35361699
- Copyright note
- © 2022 CMA Impact Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
- Grant note
- M. Lonergan received a doctoral award from the Fonds de Recherche du Québec (FRQS). S. Pigeon received a master’s award from FRQS and from the Canadian Institutes of Health Research while working on this project.
- Organisation Unit
- Thompson Institute
- Language
- English
- Record Identifier
- 991105742002621
- Output Type
- Journal article
Metrics
4 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Neurosciences
- Psychiatry
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites